These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22634880)

  • 1. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
    Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
    J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.
    Box H; Livermore J; Johnson A; McEntee L; Felton TW; Whalley S; Goodwin J; Hope WW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):278-87. PubMed ID: 26503648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
    Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of the Orotomides against
    Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
    mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
    Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
    J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
    Pfaller MA; Diekema DJ; Ghannoum MA; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Espinel-Ingroff A; Fowler CL; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Sheehan DJ; Walsh TJ;
    J Clin Microbiol; 2009 Oct; 47(10):3142-6. PubMed ID: 19692559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
    Al-Saigh R; Elefanti A; Velegraki A; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
    Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
    Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
    Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
    Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
    Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
    van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
    Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.
    Salas V; Pastor FJ; Calvo E; Sutton DA; Fothergill AW; Guarro J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1404-8. PubMed ID: 23295918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
    Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
    J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUCAST technical note on voriconazole and Aspergillus spp.
    Hope WW; Cuenca-Estrella M; Lass-Flörl C; Arendrup MC;
    Clin Microbiol Infect; 2013 Jun; 19(6):E278-80. PubMed ID: 23413937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.